BFM
BDTX icon

Boothbay Fund Management’s Black Diamond Therapeutics BDTX Stock Holding History

Boothbay Fund Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-211,600
Closed -$920K – 1507
2024
Q3 		$920K Buy
+211,600
New +$1.15M 0.02% 783

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's BDTX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2024, closing a stake of 141,347 shares — an estimated $397K sold.

Boothbay Fund Management first reported a position in BDTX in Q2 2020 and held it in 11 quarters. The position peaked at $1.3M in Q3 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Black Diamond Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 141,347 Black Diamond Therapeutics shares in Q1 2024, an estimated $397K.
  • Boothbay Fund Management first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 11 quarters.
  • Boothbay Fund Management's Black Diamond Therapeutics position peaked at $1.3M in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.